ESMO26: SANOVO data backs 1L Orpathys use in NSCLC subgroup, but AEs temper reaction - Pharmaceutical Technology

Positive Phase III results from the SANOVO and SAFFRON studies with Orpathys raise several sequencing and usage considerations. Positive Phase III results from the SANOVO and SAFFRON studies with Orpathys raise several sequencing and usage considerations. Orpathys added to Tagrisso extended median PFS to 24.8 months vs. 11.1 months with Tagrisso plus placebo in IHC 3+ NSCLC. Credit: HobbitArt/Shutterstock.com. Unlock FREE Access to Premium Content ​Discover exclusive forecasts, analyst insights, and in-depth pharmaceutical industry analysis spanning drug development, manufacturing, regulation, and global healthcare trends. With a free Pharmaceutical Technology profile, you can: The leading site for news and procurement in…

Source: Pharmaceutical Technology